secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zoetis Inc. (ZTS)
CIK:        0001555280
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001555280-24-000295
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zoetis Q2 2024: revenue $2.4B (+11% op), adj EPS $1.56 (+20% op), raises FY guidance
--------------------------------------------------------------------------------

- Revenue $2.4B, +8% reported / +11% operational; U.S. +12%, International +10% op.
- GAAP net income $624M (-7%), diluted EPS $1.37 (-6%).
- Adjusted net income $711M (+9% reported, +18% operational), adjusted diluted EPS $1.56 (+11% reported, +20% operational).
- FY2024 guidance raised: revenue $9.100-9.250B, adj EPS $5.78-5.88; op rev growth 9-11%, op adj NI growth 13.5-15.5%.
- Growth led by mAb OA pain products Librela/Solensia, Simparica Trio, and dermatology portfolio Apoquel/Cytopoint.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1555280/000155528024000295/0001555280-24-000295-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1555280/000155528024000295/zts-20240806.htm
  HTML page:      https://secwatch.observer/filing/0001555280-24-000295

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer